Anti-Infective Agents Market To Reach $144.96 Billion By 2030

Anti-Infective Agents Market Growth & Trends

The global anti-infective agents market size is estimated to reach USD 144.96 billion by 2030, expanding at a CAGR of 1.61% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of infectious diseases such as HIV, H1N1, and Ebola virus reflect the profound changes in behavioral patterns of communities over the recent decades. The societal changes and increasing awareness among healthcare professionals and patients are driving the growth.

Organizations, such as the World Health Organization (WHO) and Centers for Disease control and Prevention (CDC) are actively involved in spreading awareness amongstpeople regarding the fatal implications of infectious diseases and the importance of early treatment. The CDC has collaborated with the National Health Ministry (NHM) in an attempt to spread awareness and to enhance the treatment of communicable diseases in developing countries such as Brazil, China, Nigeria, and India.

However, introduction of novel therapeutics with increased potency and efficacy and the commercialization of pipeline products, such as commercialization of Omadacycline in 2018 for the treatment of Community Acquired Bacterial Pneumonia (CABP), are expected to propel the growth of the anti-infective agents market.

 Request a free sample copy or view report summary: Anti-Infective Agents Market Report

Anti-Infective Agents Market Report Highlights

• Antiviral was estimated to be the largest segment with a market share of 50.9% in 2024 owing to the high price associated with the new potent anti-viral drugs, such as Vicriviroc for the treatment of HIV

• Antiviral segment dominated the market with a 50.9% share in 2024. Antiviral drugs are crucial components of the anti-infective agents market, primarily used in the treatment and prevention of viral infections

• In August 2024, Shionogi & Co. announced that its New Drug Application (NDA) for cefiderocol, a novel siderophore cephalosporin antibiotic, has been accepted for review in China by the Center for Drug Evaluation. Cefiderocol targets gram-negative bacteria, including multidrug-resistant strains, and has demonstrated superior efficacy in a Phase III trial compared to imipenem/cilastatin.

• Hospital pharmacy dominated the market with the highest revenue share of 48.5% in 2024 while e-commerce is expected to be the fastest-growing segment during the forecast period

• North America dominated the global industry in 2024 and accounted for the largest share of 38.1% of the overall revenue. High prevalence of infectious diseases including hospital-acquired infections in both, children and adults, and the resultant overuse of antibiotics coupled with increased accessibility of non-prescription anti-infectives are the major drivers

• Asia Pacific is one of the fastest growing regional segments owing to the presence of high, unmet demand for novel drugs, rapid improvements in healthcare infrastructure coupled with rising awareness among healthcare professionals and patients

• Effective disease management involves a range of long-term strategies such as new product development, mergers and acquisitions, co-development, and business expansions. For instance, in January 2024, Basilea Pharmaceutica announced its acquisition of a preclinical antibiotics program from Spexis AG.

Anti-Infective Agents Market Segmentation

Grand View Research has segmented the global anti-infective agents market based on type, route of administration, distribution channel, and region:

Anti-Infective Agents Type Outlook (Revenue, USD Million, 2018 - 2030)

• Antibacterials

  • Cephalosporins

  • Penicillin

  • Fluoroquinolones

  • Macrolides

  • Carbapenem

  • Others

• Antivirals

• Antifungals

  • Azoles

  • Echinocandins

  • Polyenes

  • Others

Anti-Infective Agents Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral

• Parenteral

• Topical

• Others

Anti-Infective Agents Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Others

Anti-Infective Agents Regional Outlook (Revenue, USD Million; 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • India

  • Japan

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Anti-Infective Agents Market

• Pfizer Inc.

• Merck & Co., Inc.

• Gilead Sciences, Inc.

• AbbVie

• Bristol-Myers Squibb

• AstraZeneca

• Sandoz International GmbH

• Bayer AG

• Xellia Pharmaceuticals

• Mankind Pharma

• B. Braun SE

• Boehringer Ingelheim